Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 1 versus THYROLAR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 1 versus THYROLAR 5.
THYROLAR-1 vs THYROLAR-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyrolar-1 is a combination of levothyroxine (T4) and liothyronine (T3). T4 is converted to the active hormone T3 in peripheral tissues. Both forms bind to thyroid hormone receptors, which regulate gene transcription, influencing metabolism, growth, and development.
Thyrolar-5 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to T3 in peripheral tissues. T3 binds to thyroid hormone receptors, regulating gene transcription and increasing cellular metabolism.
Oral: 30-60 mg liothyronine (T3) daily, typically initiated at 15 mg/day and titrated upward based on clinical response. Usual maintenance dose 25-50 mg/day.
Oral, starting dose 15-30 mg daily, titrated to maintenance dose of 60-120 mg daily, divided into 2-3 doses.
None Documented
None Documented
Levothyroxine (T4): 6–7 days; Liothyronine (T3): 1–2 days. In hyperthyroidism, T4 half-life may be reduced to 3–4 days; in hypothyroidism, prolonged to 9–10 days.
Liothyronine (T3): 1-2 days; Levothyroxine (T4): 6-7 days. Clinical context: In hyperthyroidism, T4 half-life shortens to 3-4 days; in hypothyroidism, prolongs to 9-10 days
Renal excretion of iodide; after deiodination of T3 and T4, iodine is excreted in urine (∼80%) and feces (∼20%).
Renal: 40-50% (as conjugated metabolites); Fecal: 20-30% (enterohepatic recirculation); Biliary: minor
Category C
Category C
Thyroid Hormone
Thyroid Hormone